patients with high grade glioma were treated with CRT using IMRT boosts in combination with HBO therapy. Twenty four (73%) patients have a tumor with WHO classification of Grade IV, and 9 (27%) patients have a Grade III. Before CRT, tumor resection was performed in 26 (79%) patients, and tumor biopsy was in 7 (21%) patients. The protocol of RT was as follows; first, three-dimensional conformal RT were delivered 40 Gy/20 fractions (fr)/daily 2.0Gy to the GTV and surrounding edema plus 1.5 to 2.0cm as the clinical target volume extended (CTV-e). Continuously, the IMRT boosts using Cyberknife were delivered 28 Gy/8 fr/daily 3.5 Gy to the GTV and 16 Gy/8 fr/daily 2.0 Gy to the surrounding edema defined as the clinical target volume annulus (CTV-a). HBO therapy was performed immediately before each IMRT boost session, and was a single treatment for 60 minutes in a monoplace HBO chamber pressured with 100% oxygen to 2.0 atmospheres absolute. Temozolomide as a concurrent or adjuvant chemotherapy was administrated in 29 (88%) patients. Feasibility and efficacy of this combined therapy were retrospectively analyzed. Results: Planned RT dose was completed in all patients, while HBO therapy was terminated in 2 (6%) patients due to aural pain of Grade 2 at first and second session. Radiation necrosis of the brain of Grade 2 occurred in 3 (9%) patients. Acute and late toxicities were mild, no Grade 3 or higher toxicity was observed in any of the patients. The median follow-up duration was 17 months. The median local progression-free survival time was 16 months. Median overall survival times were 23 months with Grade IV and 30 months with grade III, respectively. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 resulted in better overall survival rates (p<0.01).
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. Concerning the recurrence patterns, 61.3% of these were located in-field (19 patients), 22.6% were marginal (7 patients) and 16.1% ex-field (5 patients). No influence on the recurrence pattern was observed according to sex, WHO grade, maintenance chemotherapy or MGMT methylation status whereas planning target volume (PTV) size had a significant influence on the recurrence pattern (p=0.032). PTV sizes > 75 ml were associated with a higher in-field recurrence rate and lower median post-recurrence progression-free survival (8.5 vs. 4.9 months, p=0.016). Conclusions: After the administration of re-irradiation with bevacizumab the recurrence pattern seems to be mainly centrally located. The PTV size was the main predictor for a marginal/ex-field recurrence. Purpose/Objective: The standard tools in the target volume delineation of glioblastoma multiforme (GBM) are gadolinium-enhanced T1-weighted (Gd-MRI) and T2-weighted MRI (T2-MRI); however, neither contrast enhancement nor edema are sufficient to accurately measure tumor extension in recurrent GBM. C11-methionine PET (MET-PET) is a wellestablished technique for evaluating the tumor extent for the radiation treatment planning in brain tumor and there is a relationship in localization between the MET-PET uptake and the grade of malignancy in GBM. The purpose of this work is to investigate the recognition of the tumor extent and to define the optimal margin to Gd-MRI and T2-MRI in the reirradiation planning of recurrent GBM by comparison to MET-PET. Materials and Methods: CT, MRI, and MET-PET were separately performed within 2 weeks in 25 patients with recurrent GBM for the re-irradiation planning. The Gd-MRI clinical target volume (CTV) (CTV-Gd) and the T2-MRI CTV (CTV-T2) were defined as the contrast-enhanced area on Gd-MRI and the high intensity area on T2-MRI, respectively. We defined CTV x mm (x= 5, 10, 15, 20) as x mm outside the CTV. MET-PET CTV (CTV-MPET) was defined as the area of MET accumulation, which was higher than that of normal tissue on MET-PET. A threshold value of CTV-MPET for the tumor/normal tissue index of 1.3 was considered for malignant activity. We calculated the sensitivity and specificity of CTV-Gd and CTV-T2 by comparison to CTV-MPET served as the gold standard in this study.
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Results:
The average CTV-MPET, CTV-Gd, and CTV-T2 volume were 59, 56, and 222 ml, respectively. There was no significant correlation between each type of the CTV in its size. Sensitivity of CTV-T2 5 mm (98%) was significantly higher than CTV-T2 (88%), and there was no significant difference in sensitivity between CTV-T2 5 mm and CTV-T2 10, 15, and 20 mm. Sensitivity of CTV-Gd 20 mm (97%) was lower than that of CTV-T2 5 mm. The specificity of CTV-Gd and CTV-T2 significantly decreased in accordance with increases in the margin outside the CTV-Gd and CTV-T2.
Conclusions:
In patients with recurrent GBM, CTV-Gd and CTV-T2 differed considerably from CTV-MPET. At least 5 mm margin to CTV-T2 would be necessary in the target volume delineation of recurrent GBM to cover CTV-MPET in the reirradiation planning. Purpose/Objective: The aim of this study is to evaluate the reliability of MRI fusion for the determination of target volume when performing CT based intracranial stereotactic radiosurgery. Materials and Methods: Patients treated with CT based intracranial stereotactic radiosurgery with various diagnoses are included in the study. All patients were immobilized using stereotactic thermoplastic masks prior to simulation. The planning CT was obtained both with and without iv contrast with 1mm slice thickness. The images obtained were then fused with 3D, T1 weighted MR images with contrast by two different platforms (Eclipse 10.0, Velocity 3.0 rigid and Velocity 3.0 deformable). The target volume was contoured by the same physician in four different image sets (planning CT with iv contrast, planning CT fused with MRI by Eclipse software, planning CT fused with MRI with Velocity rigid fusion algorithm software, planning CT fused with MRI with Velocity deformable fusion algorithm software). The target volumes delineated on planning CT with iv contrast were determined as reference volume. The intersections of all volumes delineated with three different fusion algorithms were produced and ratios of the intersections were calculated. Values close to one was determined as the unit of similarity and were compared with Paired-Samples t test. The center of each target was determined and offsets were calculated according to the reference. Results: Eight intracranial targets were evaluated. All of the targets evaluated were clearly visualized in the planning CT with iv contast. Six of these lesions were metastases while the remaining two were meningioma. The median volume of the delineated targets on the planning CT with iv contrast was 9.53 cc. The intersecting volume with three different fusion algorithms (Eclipse fusion, Velocity rigid fusion and Velocity deformeable fusion) was 8.08, 6.74 and 6.84 cc respectively. The ratios of the intersections were 1.20, 1.42 and 1.40 where all of these differences were significant (p=0.004, p=0.010 ve p=0.009). The maxiumum offset in each fusion was in Y axis and the most in velocity deformable fusion (mean 0.3 cm; 0.02-0.76cm). There was difference between offsets for the lesion which are close to or away from the bone. Conclusions: Determining the target volume with MRI fusion when performing CT based intracranial stereotactic radiosurgery may not be very reliable compared to obtaining a planning CT with iv contrast. Careful attention must be paid to this as this might affect not only the treatment outcomes but also the late toxicity. We evaluated the survival after initial diagnosis and after reirradiation. The prognostic factors were analysed by bivariate and multivariate Cox regression model. Results: The median age was 48 years old. The primary histology included anaplastic astrocytoma (47%) and glioblastoma (53%). A margin dose of 18Gy was administered in the majority of cases (74%). The median survival after initial diagnosis was 21 months (39 months for anaplastic astrocytoma and 18.5 months for glioblastoma) and after reirradiation was 10 months (17 months for anaplastic astrocytoma and 7.5 months for glioblastoma). In the bivariate analyses the prognostic factors significantly associated with the survival after re-irradiation were: age, tumour and treatment volume at recurrence, recursive partitioning analyses classification, karnofsky performance score, histology, and margin to the planning target volume. Only the last four showed significant association in the multivariate analyses. Conclusions: stereotactic radiosurgery is a safe and may be an effective treatment option for selected patients diagnosed with recurrent high-grade glioma. The identified prognostic factors could help to individualise the treatment. 
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